Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 7 of 65 · 3079 articles
If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...
This study reports a new engineered oral probiotic delivery system that may increase probiotic survival, target inflamed colon tissue, and change the gut microbiome in ways that reduced colitis in mice — a potential...
Diarrhea is a common, burdensome symptom in IBD. This study suggests that inflammation-linked defects in enterocyte differentiation and reduced ion transporter expression may help explain persistent diarrhea and that...
Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to...
Late-stage (Phase 3) AFFIRM data for subcutaneous Skyrizi in Crohn’s disease are being presented publicly — that could lead to new treatment options if regulators approve expanded indications, and it influences...
This study links altered autophagy genes (ATG5, ATG16L1) in Crohn’s disease and ulcerative colitis with modulation by the gut bacterium Akkermansia muciniphila and its extracellular vesicles, suggesting a possible...
Intestinal fibrosis can cause strictures and obstructive complications that often lead to surgery. Research identifying the cellular drivers and druggable pathways could guide development of treatments to prevent or slow...
People with ulcerative colitis often face trial‑and‑error when starting advanced therapies. THAMES‑IBD aims to find biological and psychosocial markers that predict who will respond, which could eventually make treatment...
The study found higher recorded rates of hidradenitis suppurativa in people with Crohn’s disease and psoriatic arthritis, and a smaller increase in ulcerative colitis, suggesting clinicians should consider asking about...
Positive phase 3 results for a subcutaneous risankizumab induction regimen may expand access to an IL‑23 p19 therapy option that avoids IV induction and showed strong short-term remission and endoscopic response rates in...
Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...
Fusing blood tests, CT enterography radiomics, and deep-learning analysis of deep small-bowel endoscopy images may improve detection of active small-bowel Crohn’s disease — a common clinical challenge because many...
This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...
This registry study offers real-world data on ozanimod effectiveness, persistence, and safety in UC patients, which can help patients and clinicians set expectations beyond clinical trial settings.
Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...
A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...
This study describes a prototype smart oral capsule that senses colonic inflammation and releases budesonide locally, which could reduce systemic exposure and allow on‑demand, lesion‑specific treatment if translated to...
Based on the title and source metadata, this appears to be a conference abstract related to Research and clinical trials. The original article is from firstwordpharma.com.
Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.
This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
Noninvasive imaging that better separates inflammation from fibrosis and detects penetrating complications could change monitoring and treatment decisions in IBD and reduce radiation exposure for patients needing...
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
The study suggests psychological (emotional) stress can worsen colitis-like inflammation via GSK3β-mediated neuroimmune changes, and that a probiotic (VSL#3) reduced many adverse effects in mice — relevant to...
The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...
The paper suggests serum bilirubin levels statistically explain a meaningful fraction of the link between gut Enterobacterales abundance and endoscopic disease activity in UC, which may point to biologic pathways or...
The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...
TG2 produced by intestinal myofibroblasts may drive fibrosis and strictures in Crohn's disease independently of inflammation; blocking TG2 reduced fibrosis in lab and mouse models, pointing to a possible new...
This large, long-term study suggests that having pets or farm animals during pregnancy or early childhood probably does not meaningfully change a child’s later risk of developing IBD, which may reassure families...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Digestive and liver...
New Phase 3 data suggest subcutaneous risankizumab (Skyrizi) can achieve meaningful endoscopic remission and ulcer-free endoscopy rates in adults with active Crohn's disease, including higher responses in patients...
Endoscopic remission (visual healing) is linked to better long-term outcomes in Crohn's disease. An approved subcutaneous induction option could make risankizumab easier to use outside infusion settings.
MASLD was common in this IBD cohort and became more frequent as BMI increased; clinicians and patients may need to consider liver health when managing IBD, especially for people with overweight or obesity.
Earlier identification of people likely to develop IBD could shorten diagnostic delays that are linked to worse outcomes, and an automated EHR model might help target who should get earlier evaluation.
The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.
RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Research and clinical trials. The original article is from moomoo.com.
This trial focuses on fibrostenosing Crohn’s disease, a form of IBD where strictures can block the intestine; a successful drug could offer a medical option to improve endoscopic passability and reduce need for...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.
This advances a drug candidate (ontunisertib) aimed specifically at fibrostenosing Crohn’s disease — a form of IBD where strictures can block the bowel and endoscopic passability is a meaningful clinical measure.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ontunisertib, Investigational or Emerging, and Research and clinical...
A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Risankizumab, and IL-23 inhibitor. Open the original article for the full details.
New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical journal...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical journal...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Gut.
